Oxford Nanopore Technologies: Alan Aubrey

Oct 25, 2021

Alan Aubrey stepped down as non-executive director of Oxford Nanopore Technologies earlier this month, following the company's recent IPO on the London Stock Exchange. He also retired from his post as CEO of IP Group, Oxford Nanopore's largest shareholder prior to the IPO.

Breaking News

Lunaphore Technologies, Cell Signaling Technology Partner on Antibody-Based Spatial Proteomics
North African Agriculture Influenced by Incoming Neolithic Populations From Europe, the Levant
Lyric, Concert Genetics Partner to Improve Genetic Testing Claims Payment Accuracy
CMS Contractor Novitas Rescinds Coverage for Multiple Cancer Genetic Tests
FDA Grants Marketing Authorization for Cue Health COVID-19 At-Home Molecular Test

The Scan

Cancer Survival Linked to Mutational Burden in Pan-Cancer Analysis

A pan-cancer paper appearing in JCO Precision Oncology suggests tumor mutation patterns provide clues for predicting cancer survival that are independent of other prognostic factors.

Australian Survey Points to Public Support for Genetic Risk Disclosure in Relatives of At-Risk Individuals

A survey in the European Journal of Human Genetics suggests most adult Australians are in favor of finding out if a relative tests positive for a medically actionable genetic variant.

Study Links Evolution of Stony Coral Skeleton to Bicarbonate Transporter Gene

A PNAS paper focuses on a skeleton-related bicarbonate transporter gene introduced to stony coral ancestors by tandem duplication.

Hormone-Based Gene Therapy to Sterilize Domestic Cat

A new paper in Nature Communication suggests that gene therapy could be a safer alternative to spaying domestic cats.